Press release
Parkinson's Disease Psychosis Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, ROA, MOA and Companies by DelveInsight | Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals, Otsuka America Pharmaceutical, more
Parkinson's Disease Psychosis Clinical Trials
In the Parkinson's Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Parkinson's disease Psychosis Pipeline treatment landscape of the report, click here @ Parkinson's Disease Psychosis Pipeline Outlook- https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Parkinson's Disease Psychosis Pipeline Report
• DelveInsight's Parkinson's Disease Psychosis Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading companies are working in the Parkinson's Disease Psychosis market include Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
• Promising Parkinson's Disease Psychosis Pipeline Therapies in the various stages of development include SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
• On Februray 2023, Annovis Bio Inc announced a study of phase 1 & 2 clinical trials for Posiphen. Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD).
• On May 2023, Stanford University announced a study of phase 4 clinical trials for Sodium Oxybate. This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used "off label" to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).
Parkinson's Disease Psychosis Overview
Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition.
For further information, refer to the detailed Parkinson's Disease Psychosis Unmet Needs, click here for Parkinson's Disease Psychosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's Disease Psychosis Emerging Drugs Profile
• Iloperidone: Vanda Pharmaceuticals
Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.
• Ulotaront: Sumitomo Pharma
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Parkinson's Disease Psychosis Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies Parkinson's disease psychosis. The Parkinson's Disease Psychosis companies which have their Parkinson's disease psychosis drug candidates in the most advanced stage, i.e phase II include Vanda Pharmaceuticals.
Request a sample and discover the recent advances in Parkinson's Disease Psychosis Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Parkinson's Disease Psychosis Segmentation- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Parkinson's Disease Psychosis Drugs and Companies
• SEP-363856: Sumitomo Pharma America Inc.
• Iloperidone: Vanda Pharmaceuticals
• Pimavanserin: Acadia Pharmaceuticals Inc.
Parkinson's Disease Psychosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Parkinson's Disease Psychosis Therapeutics Market include-
Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
Dive deep into rich insights for drugs for Parkinson's Disease Psychosis Pipeline, click here @ Parkinson's Disease Psychosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Parkinson's Disease Psychosis Pipeline Report
• Coverage- Global
• Companies- Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
• Therapies- SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Parkinson's Disease Psychosis Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's disease psychosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's disease psychosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Iloperidone: Vanda Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's disease psychosis Key Companies
21. Parkinson's disease psychosis Key Products
22. Parkinson's disease psychosis- Unmet Needs
23. Parkinson's disease psychosis- Market Drivers and Barriers
24. Parkinson's disease psychosis- Future Perspectives and Conclusion
25. Parkinson's disease psychosis Analyst Views
26. Parkinson's disease psychosis Key Companies
27. Appendix
Trending Report :
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/bardet-biedl-syndrome-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Bronchiolitis Obliterans Syndrome Bos Market: https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-nec-epidemiology-forecast
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Spasticity Market: https://www.delveinsight.com/report-store/spasticity-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Thrombotic Microangiopathy Market: https://www.delveinsight.com/report-store/thrombotic-microangiopathy-tma-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Psychosis Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, ROA, MOA and Companies by DelveInsight | Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals, Otsuka America Pharmaceutical, more here
News-ID: 3664551 • Views: …
More Releases from DelveInsight Business Research
Oral Mucositis Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapi …
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Oral Mucositis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oral Mucositis NDA approvals (if any), and…
Necrotizing Enterocolitis Clinical Trials 2024: FDA Approvals, Pipeline, Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Necrotizing Enterocolitis pipeline constitutes 4+ key companies continuously working towards developing 4+ Necrotizing Enterocolitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Necrotizing Enterocolitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Necrotizing Enterocolitis Market.
The Necrotizing Enterocolitis Pipeline report embraces…
Bunion (Hallux Valgus) Treatment Market Outlook 2034: FDA Approvals, Clinical Tr …
(openPR) - (Albany, USA) DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/bunion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of…
Bunion (Hallux Valgus) Treatment Market 2034: FDA Approvals, Clinical Trials, Pr …
(Albany, USA) DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/bunion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Bunion…
More Releases for Parkinson
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency.
The firm recognised that to continue delivering high quality services to its clients it needed to provide…
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold
Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global…
PARKINSON RESEARCH FOUNDATION Announces Director of Patient Programs, Services a …
The Parkinson Research Foundation is pleased to announce that Marilyn Tait has joined the foundation as the Director of Patient Programs, Services and Advocacy. Tait, is a graduate of Thomas Jefferson University School of Nursing in Philadelphia, Pennsylvania. Tait has forty years experience in healthcare marketing and program development. After specializing in oncology for 30 years, Tait embarked on her new career at a time in her life when…
PARKINSON RESEARCH FOUNDATION’S (PRF) WESTERN CARIBBEAN FOURTH EDUCATIONAL CRU …
The Parkinson Research Foundation (PRF), a non-profit organization with a dedicated patient education program, will return to the Western Caribbean for its fourth educational cruise. PRF developed its educational cruise program to give Parkinson patients, caregivers family and loved ones unrivaled access to experts in the movement-disorder field.
After visiting the Bahamas and Alaska on the first two respective PRF cruises, PRF’s ventured to the Western Caribbean on its most…
PARKINSON RESEARCH FOUNDATION (PRF) Develops New Patient Outreach Program
One of the principal missions of the Parkinson Research Foundation (PRF) that distinguishes it from other Parkinson organizations is PRF’s focus on patient education; specifically education that enables Parkinson patients and their caregivers to live fuller and more comfortable lives with Parkinson's disease.
The Foundation’s educational events, including educational cruises, gather leading Parkinson experts, therapists and nutritionists from across the country to offer life-changing tools and knowledge for individuals affected…
Parkinson`s Disease:New Hope Educational Conference
PARKINSON’S DISEASE: NEW HOPE EDUCATIONAL CONFERENCE
Become knowledgeable about the advancements in surgery
The Parkinson Research Foundation is proud to announce that Dr. James Schumacher will be speaking about advances in surgery at our fourth annual New Hope for Parkinson’s conference on November 1st in Boca Raton. Dr. Schumacher is an internationally known expert in the field of neurosurgical treatment of Parkinson’s disease and movement disorders. He has an extensive background and…
